Swedish biotechnology company Diamyd Medical AB (Nasdaq First North Growth Market:DMYD-B) on Tuesday announced that the South Korean Patent Office has granted a patent for the use of insulin-based antigens to treat autoimmune diabetes in patients with the HLA DR4-DQ8 genetic marker.
This patent, valid until 2035, is the first of its kind globally and reinforces the importance of precision medicine in diabetes care.
Diamyd Medical is currently conducting a Phase 3 trial with its GAD-specific immunotherapy Diamyd in patients with HLA DR3-DQ2, another genetically distinct subgroup of Type 1 diabetes patients.
Up to 90% of Type 1 diabetes patients carry either the HLA DR3-DQ2 or HLA DR4-DQ8 genetic markers.
AstraZeneca to invest USD2bn in major Maryland manufacturing expansion
European Commission approves Celltrion's Remsima IV liquid formulation
TIRmed Pharma partners with Bachem to advance production of atopic dermatitis therapy
Fondazione Telethon reports positive opinion for Waskyra marketing authorisation in Europe
Vascarta and CUNY report positive preclinical results in glioblastoma treatment
Cellipont Bioservices and Ernexa Therapeutics form cell therapy partnership
Hemogenyx Pharmaceuticals advances HG-CT-1 trial and opens paediatric recruitment
Merck KGaA to acquire JSR Life Sciences chromatography business to expand Protein A capabilities
Bristol Myers Squibb to acquire Orbital Therapeutics for USD1.5bn to expand cell therapy portfolio
Celltrion launches AVTOZMA IV in the United States following FDA approval
OSE Immunotherapeutics forms strategic alliance with Inserm Transfert and Nantes University